Skip to main content

Table 2 Anticoagulation indicators

From: Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients

 

Group D

Group A

Group P

1 week

2 week

1 week

2 week

1 week

2 week

APTT

(24–34 s)

47.3 ± 9.7

50.1 ± 12.2

33.6 ± 4.9

31.8 ± 5.4

29.8 ± 2.3

30.0 ± 2.2

PT

(11–14 s)

16.4 ± 1.9

16.3 ± 1.8

15.4 ± 2.6

15.0 ± 2.3

13.1 ± 0.5

13.0 ± 0.6

F1 + 2

(69–229 pmol/l)

150.4 ± 62.3

159.0 ± 62.1

130.9 ± 40.5

182.0 ± 116.6

230.7 ± 59.9

247.2 ± 76.9

IL-6

(< 8 pg/ml)

2.9 ± 4.2

2.3 ± 1.4

5.1 ± 4.8

3.1 ± 1.9

5.3 ± 6.7

2.4 ± 2.5

hsCRP

(< 0.30 mg/dl)

0.10 ± 0.14

0.11 ± 0.13

0.22 ± 0.21

0.20 ± 0.19

0.19 ± 0.20

0.12 ± 0.16

PTX3

(0.73–5.49 ng/ml)

3.4 ± 3.8

2.9 ± 2.4

3.9 ± 2.8

3.5 ± 2.1

3.3 ± 2.5

3.0 ± 2.3

  1. Normal range of each factor is indicated in parentheses. Data are presented as average ± standard deviation
  2. APTT activated partial thromboplastin time, PT prothrombin time, F1 + 2 prothrombin fragment, IL-6 interleukin 6, hsCRP high sensitivity C-reactive protein, PTX3 pentraxin 3